|
AbbVie
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab) ($14billion in 2023 revenues, 27percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7billion in 2023 revenues), Imbruvica to treat cancer ($3.6billion in 2023 revenues), Rinvoq to treat arthritis ($4billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7billion in 2023 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AbbVie Logo
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab) ($14billion in 2023 revenues, 27percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7billion in 2023 revenues), Imbruvica to treat cancer ($3.6billion in 2023 revenues), Rinvoq to treat arthritis ($4billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7billion in 2023 revenues), a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Humira
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor-alpha ( TNFα). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002. It ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Adalimumab
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor-alpha ( TNFα). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Imbruvica
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also binds to C-terminal Src Kinases. These are off-target receptors for the BTK inhibitor. Ibrutinib binds to these receptors and inhibits the kinase from promoting cell differentiation and growth. This leads to many different side effects like left atrial enlargement and atrial fibrillation during the treatment of Chronic Lymphocytic Leukemia. It is on the World Health Organization's List of Essential Medicines. Medical uses Ibrutinib is indicated for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic l ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
List Of Largest Biomedical Companies By Revenue
The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least , ranked by their revenue in the respective financial year. It does not include biotechnology companies that are now owned by, or form a part of, larger pharmaceutical groups. Ranking by revenue The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa. Green cells indicate years where revenue increased compared to the preceding year. Red cells indicate those years when there has been a decrease. See also * List of largest biomedical companies by market capitalization References {{DEFAULTSORT:List Of Biotechnology Companies Biotechnology Biomedical ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Rinvoq
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. Upadacitinib was approved for medical use in both the United States and the European Union in 2019. Medical uses Upadacitinib is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is indicated for the treatme ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Venetoclax
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML). The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness. Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease. Medical uses CLL/SLL In the US, venetoclax is indicated for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Indication does not depend on mutation status (e. g. 17p deletion, IGHV mutation, 12+). In th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ritonavir
Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. This combination treatment is known as highly active antiretroviral therapy (HAART). Ritonavir is a protease inhibitor, though it now mainly serves to boost the potency of other protease inhibitor (pharmacology), protease inhibitors. It may also be used in combination with other medications to treat hepatitis C and COVID-19. It is taken Oral administration, by mouth. Common side effects of ritonavir include nausea, vomiting, loss of appetite, diarrhea, and numbness of the hands and feet. Serious side effects include liver complications, pancreatitis, allergic reactions, and arrhythmias. Serious interactions may occur with a number of other medications including amiodarone and simvastatin. At low doses, it is considered to be acceptable for use during pregnancy. Ritonavir is of the protease inhibitor class. However, it is also commonly used to inhibi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Risankizumab
Risankizumab, sold under the brand name Skyrizi ( ), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection. The most common side effects include upper respiratory infections (nose and throat infection). Risankizumab is approved for medical use in the European Union, Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. the United States, Canada, and Japan. Medical uses Risankizumab is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. In Japan, it is also indicated for the treatment of generalized pustular psoriasis and erythrodermic psoriasis. Adverse effects Injection site reactions, such as redness and pain, have been reported but are uncommon, be ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C. It contains glecaprevir and pibrentasvir. It works against all six types of hepatitis C. At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. It is taken once a day by mouth with food. The most common side effects are headache, diarrhea, and tiredness. In those with a history of hepatitis B, reactivation may occur. It is not recommended in people with moderate to severe liver disease. Glecaprevir works by blocking the protein NS3/ 4A protease, while pibrentasvir works by blocking NS5A. The combination was approved for medical use in the United States and Europe in 2017. It is on the World Health Organization's List of Essential Medicines. Medical uses In the United States, G/P is used to treat adults and children aged 12 years and older or weighing at least 99 pounds with chronic ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
